BioAge Labs (NASDAQ:BIOA) Shares Gap Down – Should You Sell?

Shares of BioAge Labs, Inc. (NASDAQ:BIOA) gapped down before the market opened on Monday . The stock had previously closed at $22.27, but opened at $20.03. BioAge Labs shares last traded at $21.1950, with a volume of 105,899 shares.

Analysts Set New Price Targets

A number of research firms have issued reports on BIOA. Oppenheimer initiated coverage on BioAge Labs in a research note on Wednesday, February 25th. They issued an “outperform” rating and a $60.00 target price on the stock. Morgan Stanley set a $23.00 price objective on shares of BioAge Labs in a research report on Wednesday, February 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of BioAge Labs in a research note on Tuesday, January 27th. Piper Sandler assumed coverage on shares of BioAge Labs in a research note on Tuesday, January 27th. They issued an “overweight” rating on the stock. Finally, Wall Street Zen raised BioAge Labs from a “sell” rating to a “hold” rating in a report on Tuesday, February 3rd. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $32.67.

BioAge Labs Stock Down 5.8%

The business has a 50-day simple moving average of $18.60 and a two-hundred day simple moving average of $11.23. The stock has a market capitalization of $733.49 million, a price-to-earnings ratio of -13.46 and a beta of 1.22.

Insider Activity at BioAge Labs

In related news, CFO Dov A. Md Goldstein sold 27,000 shares of the firm’s stock in a transaction dated Tuesday, January 13th. The stock was sold at an average price of $19.70, for a total transaction of $531,900.00. Following the completion of the transaction, the chief financial officer owned 22,408 shares of the company’s stock, valued at $441,437.60. This trade represents a 54.65% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Kristen Fortney sold 233,107 shares of BioAge Labs stock in a transaction dated Tuesday, January 13th. The stock was sold at an average price of $18.12, for a total value of $4,223,898.84. Following the transaction, the chief executive officer directly owned 976,949 shares in the company, valued at approximately $17,702,315.88. The trade was a 19.26% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 354,437 shares of company stock valued at $5,813,228 over the last 90 days. 20.82% of the stock is currently owned by corporate insiders.

Institutional Trading of BioAge Labs

A number of hedge funds and other institutional investors have recently made changes to their positions in BIOA. Invesco Ltd. acquired a new stake in BioAge Labs during the fourth quarter valued at approximately $3,025,000. XTX Topco Ltd bought a new position in shares of BioAge Labs in the fourth quarter valued at $486,000. Sphera Funds Management LTD. acquired a new stake in shares of BioAge Labs during the 4th quarter valued at $3,215,000. Quadrature Capital Ltd boosted its stake in shares of BioAge Labs by 56.2% during the 4th quarter. Quadrature Capital Ltd now owns 16,769 shares of the company’s stock worth $222,000 after acquiring an additional 6,035 shares in the last quarter. Finally, Janus Henderson Group PLC acquired a new position in shares of BioAge Labs in the 4th quarter worth $5,406,000.

BioAge Labs Company Profile

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.